ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/ERBB2-inhibitor-third-generation
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/ERBB2-inhibitor-third-generation
2
trial(s) found.
NCT07413939
Advanced
Phase 2 / Phase 3
Recruiting
A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases (
BREnnA
)
ERBB2 inhibitor
ERBB2 inhibitor,third generation
anti-ERBB2 monoclonal antibody
fluoropyrimidine
HER2-positive breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NCT05253651
Advanced
Phase 3
Recruiting
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer (
MOUNTAINEER-03
)
ERBB2 inhibitor,third generation
anti-EGFR monoclonal antibody
anti-ERBB2 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Recruitment Country and State
NSW (2)
VIC (2)
NZ (1)
QLD (1)
Phase
Phase 2 / Phase 3 (1)
Phase 3 (1)
Trial Type
Advanced (2)
Cancer Therapy Class
ERBB2
100%
EGFR
50%
VEGF
50%
Facility
2109 - North Ryde - Macquarie University Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
Cancer Type
Cancer
Solid tumour
Breast adenocarcinoma
Breast cancer
HER2-positive breast cancer
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy